Identification

Name
Amlodipine
Accession Number
DB00381  (APRD00520)
Type
Small Molecule
Groups
Approved
Description

Amlodipine is a long-acting 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, amlodipine prevents calcium-dependent myocyte contraction and vasoconstriction. A second proposed mechanism for the drug’s vasodilatory effects involves pH-dependent inhibition of calcium influx via inhibition of smooth muscle carbonic anhydrase. Some studies have shown that amlodipine also exerts inhibitory effects on voltage-gated N-type calcium channels. N-type calcium channels located in the central nervous system may be involved in nociceptive signaling and pain sensation. Amlodipine is used to treat hypertension and chronic stable angina.

Structure
Thumb
Synonyms
  • (RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
  • 3-Ethyl 5-methylester, (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
  • Amlodipine
  • Amlodipine free base
  • Amlodipino
  • Amlodipinum
Product Ingredients
IngredientUNIICASInChI Key
Amlodipine besylate864V2Q084H111470-99-6ZPBWCRDSRKPIDG-UHFFFAOYSA-N
Amlodipine maleateCQ27G2BZJM88150-47-4TZNOWAJJWCGILX-BTJKTKAUSA-N
Amlodipine mesylate291Y33EZHA246852-12-0MUVFCHUBATVFPP-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act AmlodipineTablet10 mgOralActavis Pharma Company2009-07-10Not applicableCanada
Act AmlodipineTablet5 mgOralActavis Pharma Company2009-07-10Not applicableCanada
Act AmlodipineTablet2.5 mgOralActavis Pharma Company2010-03-02Not applicableCanada
AmlodipineTablet10 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
AmlodipineTablet5 mgOralMeliapharm Inc2011-04-082014-06-25Canada
AmlodipineTablet5 mgOralJamp Pharma Corporation2014-09-04Not applicableCanada
AmlodipineTablet10 mgOralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
AmlodipineTablet2.5 mgOralPro Doc Limitee2009-07-22Not applicableCanada
AmlodipineTablet10 mgOralSanis Health Inc2009-10-22Not applicableCanada
AmlodipineTablet5 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-amlodipineTablet10 mgOralAccel Pharma Inc2010-03-052016-10-19Canada
Accel-amlodipineTablet2.5 mgOralAccel Pharma IncNot applicableNot applicableCanada
Accel-amlodipineTablet5 mgOralAccel Pharma Inc2010-03-052016-10-19Canada
Ag-amlodipineTablet10 mgOralAngita Pharma Inc.2014-09-25Not applicableCanada
Ag-amlodipineTablet2.5 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-amlodipineTablet5 mgOralAngita Pharma Inc.2014-09-25Not applicableCanada
AmlodipineTablet10 mg/1OralRemedy Repack2011-04-132016-10-13Us
AmlodipineTablet10 mg/1OralMacleods Pharmaceuticals Limited2012-04-13Not applicableUs
AmlodipineTablet10 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
AmlodipineTablet5 mg/1OralMacleods Pharmaceuticals Limited2012-04-13Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AmlobenzAmlodipine besylate (5 mg/1) + Benazepril hydrochloride (10 mg/1)CapsuleOralRebel Distributors2010-04-19Not applicableUs55111 0339 01 nlmimage10 6d03b6bd
AmlobenzAmlodipine besylate (10 mg/1) + Benazepril hydrochloride (20 mg/1)CapsuleOralRebel Distributors2010-04-19Not applicableUs55111 0341 01 nlmimage10 c238e107
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (10 mg/1) + Benazepril hydrochloride (20 mg/1)CapsuleOralMylan Pharmaceuticals2012-02-20Not applicableUs
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (5 mg/1) + Benazepril hydrochloride (40 mg/1)CapsuleOralbryant ranch prepack2012-09-05Not applicableUs
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (5 mg/1) + Benazepril hydrochloride (20 mg/1)CapsuleOralNu Care Pharmaceuticals,inc.2012-09-05Not applicableUs
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (5 mg/1) + Benazepril hydrochloride (10 mg/1)CapsuleOralAurobindo Pharma2012-09-05Not applicableUs65862 0583 01 nlmimage10 6039b03d
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (10 mg/1) + Benazepril hydrochloride (40 mg/1)CapsuleOralNu Care Pharmaceuticals,inc.2012-09-05Not applicableUs
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (2.5 mg/1) + Benazepril hydrochloride (10 mg/1)CapsuleOralApotex Corporation2013-12-30Not applicableUs
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (5 mg/1) + Benazepril hydrochloride (40 mg/1)CapsuleOralNu Care Pharmaceuticals,inc.2012-09-05Not applicableUs
Amlodipine and Benazepril HydrochlorideAmlodipine besylate (2.5 mg/1) + Benazepril hydrochloride (10 mg/1)CapsuleOralActavis Pharma Company2010-10-13Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
HypertenipineAmlodipine besylate + L-ArginineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
ImpridaAmlodipine (10 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2007-01-172017-05-11Eu
ImpridaAmlodipine (5 mg) + Valsartan (80 mg)Tablet, film coatedOralNovartis Europharm Limited2007-01-172017-05-11Eu
ImpridaAmlodipine (10 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2007-01-172017-05-11Eu
ImpridaAmlodipine (5 mg) + Valsartan (80 mg)Tablet, film coatedOralNovartis Europharm Limited2007-01-172017-05-11Eu
ImpridaAmlodipine (5 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2007-01-172017-05-11Eu
ImpridaAmlodipine (10 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2007-01-172017-05-11Eu
ImpridaAmlodipine (5 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2007-01-172017-05-11Eu
ImpridaAmlodipine (10 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2007-01-172017-05-11Eu
ImpridaAmlodipine (10 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2007-01-172017-05-11Eu
International/Other Brands
Aforbes (Merck) / Agen (Zentiva) / Aken (Kendrick Farmaceutica) / Amcard (Apex Pharma Ltd) / Amdepin (Cadila Pharmaceuticals) / Amdipin (Laboratorios Lafrancol) / Amlocard (AWD (Germany)) / Amlod / Amlodine (Sumitomo Pharmaceuticals) / Amlodipin / Amlodipin-Mepha 5/10 (Mepha Pharma AG) / Amlodipine 5 (PT KALBE FARMA Tbk) / Amlodis (Eczacibasi (Turkey)) / Amlong (Micro Labs) / Amlopin (Lek) / Amlopine (Berlin) / Amlostin (Discovery Pharmaceuticals) / Amlosun (Sun Pharmaceutical) / Amlovas (Macleods Pharmaceuticals Ltd) / Amlovasc (Dr. Reddy's Laboratories) / Amlozek (Adamed) / Amvaz (Reddy (Malaysia)) / Asomex (Emcure Pharmaceuticals) / Atecard-AM (Alembic Ltd) / Camlodin (Square) / Coroval (Sandoz (Argentina)) / Dailyvasc (Xeno Pharmaceuticals) / Istin / Lama (Stadmed Private Limited) / Lodip (TIME Pharmaceuticals) / Lodopin (Merck Pakistan) / Lopin (Edruc Ltd) / Nelod (The Kemiko Pharmaceuticals Ltd) / Nopidin (Ad-din Pharmaceuticals Ltd) / Nordip / Perivasc / Pharex Amlodipine (PHAREX HealthCorp) / Tenox (Krka)
Categories
UNII
1J444QC288
CAS number
88150-42-9
Weight
Average: 408.876
Monoisotopic: 408.145199627
Chemical Formula
C20H25ClN2O5
InChI Key
HTIQEAQVCYTUBX-UHFFFAOYSA-N
InChI
InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3
IUPAC Name
3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC

Pharmacology

Indication

For the treatment of hypertension and chronic stable angina.

Associated Conditions
Pharmacodynamics

Amlodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that DHP CCBs target L-type calcium channels, the major channel in muscle cells that mediate contraction; however, some studies have indicated that amlodipine also binds to and inhibits N-type calcium channels (see references in Targets section). Similar to other DHP CCBs, amlodipine binds directly to inactive L-type calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives amlodipine additional arterial selectivity. At therapeutic sub-toxic concentrations, amlodipine has little effect on cardiac myocytes and conduction cells.

Mechanism of action

Amlodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of amlodipine result in an overall decrease in blood pressure. Amlodipine is a long-acting CCB that may be used to treat mild to moderate essential hypertension and exertion-related angina (chronic stable angina). Another possible mechanism is that amlodipine inhibits vascular smooth muscle carbonic anhydrase I activity causing cellular pH increases which may be involved in regulating intracelluar calcium influx through calcium channels.

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-1
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-2
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1D
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1S
inhibitor
Human
UVoltage-dependent N-type calcium channel subunit alpha-1B
inhibitor
Human
UVoltage-dependent calcium channel subunit alpha-2/delta-3
inhibitor
Human
UVoltage-gated calcium channel beta 1 subunit splice variant CavB1d
inhibitor
Human
UCarbonic anhydrase 1
inhibitor
Human
USphingomyelin phosphodiesterase
inhibitor
Human
Absorption

Amlodipine is slowly and almost completely absorbed from the gastrointestinal tract. Peak plasma concentrations are reached 6-12 hour following oral administration. Its estimated bioavailability is 64-90%. Absorption is not affected by food.

Volume of distribution
Not Available
Protein binding

97.5%

Metabolism

Hepatic. Metabolized extensively (90%) to inactive metabolites via the cytochrome P450 3A4 isozyme.

Route of elimination

Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine.

Half life

30-50 hours

Clearance
Not Available
Toxicity

Gross overdosage could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to an including shock with fatal outcome have been reported.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Amlodipine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Natriuretic peptides A---(A;A)AA alleleEffect Directly StudiedPatients with this genotype have increased risk of adverse cardiovascular outcomes with diuretics.Details

Interactions

Drug Interactions
DrugInteractionDrug group
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Amlodipine.Investigational
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Amlodipine.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Amlodipine.Approved, Investigational
AceclofenacThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Amlodipine.Approved, Vet Approved
Acetylsalicylic acidThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Amlodipine.Approved
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Amlodipine.Investigational
AlclofenacThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlcuroniumAmlodipine may increase the neuromuscular blocking activities of Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amlodipine.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Amlodipine.Experimental, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of Amlodipine.Approved, Investigational
AliskirenAmlodipine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Amlodipine.Approved, Investigational
AlminoprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Alminoprofen.Experimental
AlprenololAmlodipine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Amlodipine.Approved, Investigational
AmifostineAmlodipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Amiloride.Approved
AminophenazoneThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Aminophenazone.Approved, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Amlodipine.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Amlodipine.Approved, Illicit
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Amlodipine.Approved
Amphotericin BAmlodipine may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Amlodipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amlodipine is combined with Amyl Nitrite.Approved
AntipyrineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Antipyrine.Approved, Investigational
AntrafenineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Antrafenine.Approved
ApalutamideThe serum concentration of Amlodipine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Amlodipine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Amlodipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Amlodipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Amlodipine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Amlodipine.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Amlodipine.Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Amlodipine.Approved, Investigational
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Amlodipine.Approved, Nutraceutical
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Amlodipine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Amlodipine.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Amlodipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Amlodipine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Amlodipine.Approved
AtracuriumAmlodipine may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateAmlodipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Amlodipine.Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Amlodipine.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Amlodipine.Approved, Investigational
AzapropazoneThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Azapropazone.Withdrawn
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Amlodipine is combined with Azilsartan medoxomil.Approved, Investigational
BalsalazideThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Amlodipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Amlodipine.Illicit
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Amlodipine.Approved, Investigational
BarnidipineAmlodipine may increase the antihypertensive activities of Barnidipine.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Amlodipine.Approved, Investigational
BenazeprilAmlodipine may increase the hypotensive activities of Benazepril.Approved, Investigational
BenazeprilatAmlodipine may increase the hypotensive activities of Benazeprilat.Experimental
BendazacThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideAmlodipine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Amlodipine.Withdrawn
BenorilateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Benzydamine.Approved
BepridilAmlodipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Amlodipine.Approved, Vet Approved
BetaxololBetaxolol may increase the hypotensive activities of Amlodipine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Amlodipine.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Amlodipine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Amlodipine.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Amlodipine.Approved, Investigational
BimatoprostAmlodipine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Amlodipine.Approved
BisoprololAmlodipine may increase the hypotensive activities of Bisoprolol.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Amlodipine.Approved
BoceprevirThe metabolism of Amlodipine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Amlodipine.Approved, Investigational
BosentanThe serum concentration of Amlodipine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Amlodipine.Approved
BQ-123Amlodipine may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amlodipine.Approved, Investigational
BretyliumAmlodipine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Amlodipine.Approved, Investigational
BromfenacThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Amlodipine.Approved, Investigational
BromperidolThe serum concentration of Bromperidol can be increased when it is combined with Amlodipine.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Amlodipine.Investigational
BufexamacThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Bufexamac.Approved, Experimental
BumadizoneThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bumetanide.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Amlodipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amlodipine.Approved, Investigational
BupranololAmlodipine may increase the hypotensive activities of Bupranolol.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Amlodipine.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Amlodipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Amlodipine.Experimental
Calcium AcetateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Phosphate.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Amlodipine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Amlodipine.Approved
CandesartanAmlodipine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilAmlodipine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilAmlodipine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilAmlodipine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Amlodipine can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Amlodipine.Approved, Investigational
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Amlodipine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Amlodipine.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Amlodipine.Withdrawn
CarprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololAmlodipine may increase the hypotensive activities of Carteolol.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Amlodipine.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Amlodipine.Approved, Investigational, Nutraceutical, Vet Approved
CelecoxibThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Amlodipine.Approved, Investigational
CeritinibThe serum concentration of Amlodipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Amlodipine.Approved, Withdrawn
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Amlodipine.Approved, Investigational
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Amlodipine.Approved
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
ChlorothiazideAmlodipine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Amlodipine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Amlodipine.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CicletanineAmlodipine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilAmlodipine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Amlodipine.Approved, Investigational
CimetidineThe serum concentration of Amlodipine can be increased when it is combined with Cimetidine.Approved, Investigational
CimicoxibThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Cimicoxib.Investigational
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Amlodipine.Approved, Investigational
CisatracuriumAmlodipine may increase the neuromuscular blocking activities of Cisatracurium.Approved
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Amlodipine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Amlodipine.Approved
ClarithromycinThe metabolism of Amlodipine can be decreased when combined with Clarithromycin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Clevidipine.Approved, Investigational
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Amlodipine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Amlodipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Amlodipine.Approved, Investigational, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Amlodipine.Approved
ClonixinThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Amlodipine.Approved
CloranololAmlodipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Amlodipine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Amlodipine.Approved
CobicistatThe metabolism of Amlodipine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Amlodipine.Approved, Investigational
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Amlodipine.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Amlodipine.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Amlodipine.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Amlodipine.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Amlodipine.Approved
CryptenamineAmlodipine may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe metabolism of Amlodipine can be decreased when combined with Curcumin.Approved, Investigational
CyclopenthiazideAmlodipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Amlodipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideAmlodipine may increase the hypotensive activities of Cyclothiazide.Approved
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Amlodipine.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Amlodipine.Approved
DabrafenibThe serum concentration of Amlodipine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Amlodipine.Approved, Investigational
DanazolThe metabolism of Amlodipine can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Amlodipine.Approved, Investigational, Withdrawn
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Amlodipine.Approved
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Amlodipine.Approved
DarunavirThe metabolism of Amlodipine can be decreased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Amlodipine.Approved
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Amlodipine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Amlodipine.Approved, Investigational
DeferasiroxThe serum concentration of Amlodipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilAmlodipine may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe metabolism of Amlodipine can be decreased when combined with Delavirdine.Approved
DeserpidineAmlodipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Amlodipine.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
DexibuprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Dexibuprofen.Approved, Investigational
DexketoprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Dexketoprofen.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dexmedetomidine.Approved, Vet Approved
DexniguldipineAmlodipine may increase the hypotensive activities of Dexniguldipine.Experimental
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Amlodipine.Approved, Illicit, Investigational, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Amlodipine.Approved
DiclofenacThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineAmlodipine may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Amlodipine.Approved, Investigational
DifenpiramideThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Difenpiramide.Experimental
DiflunisalThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Diflunisal.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Amlodipine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Amlodipine.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Amlodipine.Approved, Investigational
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Amlodipine.Approved, Investigational
DiltiazemThe metabolism of Amlodipine can be decreased when combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dinutuximab.Approved, Investigational
DipyridamoleDipyridamole may increase the antihypertensive activities of Amlodipine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Amlodipine.Approved, Investigational
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Amlodipine.Approved
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Amlodipine.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
DorzolamideAmlodipine may increase the hypotensive activities of Dorzolamide.Approved
DoxacuriumAmlodipine may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Amlodipine.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Amlodipine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Amlodipine.Approved, Investigational
DoxycyclineThe metabolism of Amlodipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Amlodipine.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Amlodipine.Approved, Vet Approved
DroxicamThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Droxicam.Withdrawn
DuloxetineAmlodipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Amlodipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Amlodipine.Approved
EfavirenzThe serum concentration of Amlodipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Amlodipine.Approved
EfonidipineAmlodipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
ElagolixThe serum concentration of Elagolix can be increased when it is combined with Amlodipine.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Amlodipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Amlodipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Empagliflozin.Approved
EnalaprilAmlodipine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatAmlodipine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Amlodipine.Experimental
EnzalutamideThe serum concentration of Amlodipine can be decreased when it is combined with Enzalutamide.Approved
EpanololAmlodipine may increase the hypotensive activities of Epanolol.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Amlodipine.Approved, Investigational
EpirizoleThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Eplerenone.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Amlodipine.Approved
EprosartanAmlodipine may increase the hypotensive activities of Eprosartan.Approved
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Amlodipine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Amlodipine.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Amlodipine.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
EsatenololAmlodipine may increase the hypotensive activities of Esatenolol.Experimental
EsmololAmlodipine may increase the hypotensive activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Amlodipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Amlodipine is combined with Etacrynic acid.Approved, Investigational
EthenzamideThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Amlodipine.Approved
EtodolacThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Amlodipine.Approved
EtoricoxibThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Amlodipine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Amlodipine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Amlodipine.Approved
FelbinacThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Felbinac.Experimental
FelodipineAmlodipine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Fenbufen.Approved
FenoldopamAmlodipine may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Fenoprofen.Approved
FentiazacThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Fentiazac.Experimental
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Amlodipine.Experimental
FeprazoneThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Feprazone.Experimental
Ferulic acidAmlodipine may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amlodipine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Amlodipine.Approved, Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Amlodipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Amlodipine.Approved, Investigational
FirocoxibThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Firocoxib.Experimental, Vet Approved
FloctafenineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Floctafenine.Approved, Withdrawn
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Amlodipine.Approved
FluconazoleThe serum concentration of Amlodipine can be increased when it is combined with Fluconazole.Approved, Investigational
FlunixinThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Flunoxaprofen.Experimental
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Amlodipine.Approved, Investigational, Withdrawn
FlurbiprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Amlodipine.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Amlodipine.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Amlodipine.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Amlodipine.Experimental
FluvoxamineThe metabolism of Amlodipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Amlodipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Amlodipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilAmlodipine may increase the hypotensive activities of Fosinopril.Approved
FosinoprilatAmlodipine may increase the hypotensive activities of Fosinoprilat.Experimental
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Amlodipine.Approved, Investigational
FostamatinibFostamatinib may increase the antihypertensive activities of Amlodipine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Amlodipine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Amlodipine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GallamineAmlodipine may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideAmlodipine may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Amlodipine.Approved, Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Amlodipine.Approved, Investigational
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Amlodipine.Approved, Investigational
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Amlodipine.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Amlodipine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Amlodipine.Approved, Investigational, Withdrawn
GuacetisalThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Guacetisal.Experimental
GuanabenzAmlodipine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Amlodipine.Approved
GuanazodineAmlodipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineAmlodipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Amlodipine.Approved, Investigational
GuanoclorAmlodipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzAmlodipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanAmlodipine may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Amlodipine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Amlodipine.Experimental
HexamethoniumAmlodipine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Amlodipine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Amlodipine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Amlodipine.Approved
HydrochlorothiazideAmlodipine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Amlodipine resulting in a loss in efficacy.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Amlodipine.Approved, Vet Approved
HydroflumethiazideAmlodipine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydroxyureaThe serum concentration of Hydroxyurea can be increased when it is combined with Amlodipine.Approved
IbuprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Ibuproxam.Withdrawn
IcosapentThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Icosapent.Approved, Nutraceutical
IdelalisibThe metabolism of Amlodipine can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Amlodipine.Approved
IloprostIloprost may increase the hypotensive activities of Amlodipine.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Amlodipine.Approved
ImidaprilAmlodipine may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Amlodipine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Amlodipine.Approved
IndapamideAmlodipine may increase the hypotensive activities of Indapamide.Approved
IndenololAmlodipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Amlodipine can be decreased when combined with Indinavir.Approved
IndobufenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Amlodipine.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Amlodipine.Approved, Investigational
IproniazidIproniazid may increase the hypotensive activities of Amlodipine.Withdrawn
IrbesartanAmlodipine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Amlodipine.Approved, Investigational
IsavuconazoleThe serum concentration of Amlodipine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Amlodipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Amlodipine.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Amlodipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Amlodipine.Approved, Vet Approved
IsoniazidThe metabolism of Amlodipine can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Amlodipine is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Amlodipine is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Amlodipine.Approved, Investigational
ItraconazoleThe metabolism of Amlodipine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Amlodipine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Ivosidenib can be increased when it is combined with Amlodipine.Approved, Investigational
KebuzoneThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Amlodipine.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Amlodipine.Approved
KetoconazoleThe metabolism of Amlodipine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Amlodipine.Approved
LacidipineAmlodipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Amlodipine.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Amlodipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Amlodipine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Amlodipine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Amlodipine.Approved, Investigational
LatanoprostAmlodipine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Amlodipine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Amlodipine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Amlodipine.Approved, Investigational
LercanidipineAmlodipine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Amlodipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Amlodipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Amlodipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Amlodipine.Approved, Investigational
LevodopaAmlodipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Amlodipine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Amlodipine.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Amlodipine.Approved, Investigational
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Amlodipine.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Amlodipine.Approved
LinezolidLinezolid may increase the hypotensive activities of Amlodipine.Approved, Investigational
LinsidomineAmlodipine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilAmlodipine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LofexidineAmlodipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Lonazolac.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Amlodipine.Approved
LopinavirThe metabolism of Amlodipine can be decreased when combined with Lopinavir.Approved
LornoxicamThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Amlodipine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Amlodipine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Amlodipine.Approved, Investigational
LoxoprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Amlodipine.Approved, Investigational
LuliconazoleThe serum concentration of Amlodipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Amlodipine can be increased when combined with Lumacaftor.Approved
LumiracoxibThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Lumiracoxib.Approved, Investigational
LusutrombopagThe serum concentration of Lusutrombopag can be increased when it is combined with Amlodipine.Approved, Investigational
MacitentanAmlodipine may increase the hypotensive activities of Macitentan.Approved
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Amlodipine.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Amlodipine.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Amlodipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Amlodipine is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Amlodipine.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Amlodipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Amlodipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineAmlodipine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Amlodipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Amlodipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Amlodipine.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Mefenamic acid.Approved
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Amlodipine.Approved, Investigational
MelatoninMelatonin may decrease the antihypertensive activities of Amlodipine.Approved, Nutraceutical, Vet Approved
MeloxicamThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MelphalanThe serum concentration of Melphalan can be increased when it is combined with Amlodipine.Approved
MesalazineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Amlodipine.Approved
MethoserpidineAmlodipine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Amlodipine.Approved
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Amlodipine.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amlodipine.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Amlodipine.Approved
MethyldopaAmlodipine may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Amlodipine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Amlodipine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Amlodipine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Amlodipine.Approved, Vet Approved
MetipranololAmlodipine may increase the hypotensive activities of Metipranolol.Approved
MetocurineAmlodipine may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideAmlodipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneAmlodipine may increase the hypotensive activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Amlodipine.Approved, Investigational
MetyrosineAmlodipine may increase the hypotensive activities of Metyrosine.Approved
MibefradilThe metabolism of Amlodipine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Amlodipine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Amlodipine can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Amlodipine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Amlodipine.Approved, Vet Approved
MinoxidilMinoxidil may increase the hypotensive activities of Amlodipine.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Amlodipine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Amlodipine.Investigational
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Amlodipine.Approved
MitotaneThe serum concentration of Amlodipine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Amlodipine.Approved, Investigational
MivacuriumAmlodipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Amlodipine.Approved, Investigational
ModafinilThe serum concentration of Amlodipine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilAmlodipine may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Amlodipine.Approved, Investigational
MorniflumateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Morniflumate.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Amlodipine.Approved, Investigational
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
MoxonidineMoxonidine may increase the hypotensive activities of Amlodipine.Approved, Investigational
MuzolimineAmlodipine may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amlodipine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Amlodipine.Approved, Investigational
NabumetoneThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Amlodipine.Approved
NafcillinThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftopidilAmlodipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Amlodipine.Approved
NaloxoneThe metabolism of Amlodipine can be decreased when combined with Naloxone.Approved, Vet Approved
NaproxenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Naproxen.Approved, Vet Approved
NebivololAmlodipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Amlodipine.Approved, Withdrawn
NelfinavirThe metabolism of Amlodipine can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Neostigmine can be increased when it is combined with Amlodipine.Approved, Vet Approved
NepafenacThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Nepafenac.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Amlodipine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Amlodipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Amlodipine.Withdrawn
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Amlodipine.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Amlodipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Amlodipine.Approved, Investigational
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Amlodipine.Approved
NifenazoneThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Amlodipine.Experimental
NilotinibThe metabolism of Amlodipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineAmlodipine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineAmlodipine may increase the hypotensive activities of Nimodipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Amlodipine.Approved
NisoldipineAmlodipine may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineAmlodipine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Amlodipine.Approved
NitroaspirinThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideAmlodipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Amlodipine.Approved, Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Amlodipine.Approved
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Amlodipine.Approved
NS-398The therapeutic efficacy of Amlodipine can be decreased when used in combination with NS-398.Experimental
ObinutuzumabAmlodipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Amlodipine.Withdrawn
OctreotideThe serum concentration of Octreotide can be increased when it is combined with Amlodipine.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Amlodipine.Investigational
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Amlodipine.Approved, Investigational
OlaparibThe metabolism of Amlodipine can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Amlodipine.Approved, Investigational
OlsalazineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Olsalazine.Approved
OmapatrilatAmlodipine may increase the hypotensive activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Amlodipine.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Amlodipine.Experimental
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Amlodipine.Approved
OxaprozinThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Oxaprozin.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Amlodipine.Approved
OxprenololAmlodipine may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Amlodipine.Investigational, Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Amlodipine.Approved, Vet Approved
PalbociclibThe serum concentration of Amlodipine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Amlodipine.Approved
PancuroniumAmlodipine may increase the neuromuscular blocking activities of Pancuronium.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Amlodipine.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Amlodipine.Approved
PapaverineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Papaverine.Approved, Investigational
ParecoxibThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Amlodipine.Approved
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Amlodipine.Approved, Investigational
Patent BlueThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Patent Blue.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Amlodipine.Approved
PenbutololAmlodipine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Amlodipine.Experimental
PentazocineThe serum concentration of Pentazocine can be increased when it is combined with Amlodipine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Amlodipine.Approved, Investigational, Vet Approved
PentoliniumAmlodipine may increase the hypotensive activities of Pentolinium.Approved
PerindoprilAmlodipine may increase the hypotensive activities of Perindopril.Approved
PerindoprilatAmlodipine may increase the hypotensive activities of Perindoprilat.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Amlodipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Amlodipine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Amlodipine.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Amlodipine.Approved, Withdrawn
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Amlodipine.Vet Approved
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Amlodipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Amlodipine.Withdrawn
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Amlodipine.Approved
PhenylbutazoneThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Amlodipine.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Amlodipine.Approved, Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Amlodipine.Approved
PinacidilPinacidil may increase the hypotensive activities of Amlodipine.Approved
PindololAmlodipine may increase the hypotensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amlodipine.Approved, Investigational
PipecuroniumAmlodipine may increase the neuromuscular blocking activities of Pipecuronium.Approved
PirlindolePirlindole may increase the hypotensive activities of Amlodipine.Approved
PiroxicamThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Pirprofen.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Amlodipine.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Amlodipine.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Amlodipine.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Amlodipine.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Amlodipine.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Amlodipine.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Amlodipine.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Amlodipine.Approved, Vet Approved
PolythiazideAmlodipine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Amlodipine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Amlodipine.Approved, Investigational
PosaconazoleThe metabolism of Amlodipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Amlodipine.Approved, Investigational
PractololAmlodipine may increase the hypotensive activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Amlodipine.Approved, Investigational
PranoprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Amlodipine.Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Amlodipine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Amlodipine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Amlodipine.Approved, Vet Approved
PrimidonePrimidone may increase the hypotensive activities of Amlodipine.Approved, Vet Approved
ProglumetacinThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Proglumetacin.Experimental
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Amlodipine.Approved, Vet Approved
PropacetamolThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Propacetamol.Approved, Investigational
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Amlodipine.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Amlodipine.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Amlodipine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Amlodipine.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Amlodipine.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Proquazone.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Amlodipine.Approved
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Amlodipine.Approved
QuinaprilAmlodipine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinaprilatAmlodipine may increase the hypotensive activities of Quinaprilat.Experimental
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Amlodipine.Approved, Investigational
QuinineThe metabolism of Amlodipine can be increased when combined with Quinine.Approved
RamiprilRamipril may increase the hypotensive activities of Amlodipine.Approved
RamiprilatAmlodipine may increase the hypotensive activities of Ramiprilat.Experimental
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Amlodipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Amlodipine.Approved, Investigational
RapacuroniumAmlodipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Amlodipine.Approved
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Amlodipine.Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Amlodipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amlodipine.Approved
RemikirenRemikiren may increase the hypotensive activities of Amlodipine.Approved
RescinnamineAmlodipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Amlodipine.Approved, Investigational
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Amlodipine.Experimental
RifampicinThe metabolism of Amlodipine can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Amlodipine can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Amlodipine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Amlodipine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Amlodipine.Approved, Investigational
RimexoloneThe metabolism of Amlodipine can be increased when combined with Rimexolone.Approved
RiociguatAmlodipine may increase the hypotensive activities of Riociguat.Approved
RisperidoneAmlodipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Amlodipine can be decreased when combined with Ritonavir.Approved, Investigational
RituximabAmlodipine may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Amlodipine.Approved
RobenacoxibThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Robenacoxib.Experimental, Vet Approved
RocuroniumAmlodipine may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Amlodipine.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Amlodipine.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amlodipine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Amlodipine.Approved
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Amlodipine.Approved, Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Amlodipine.Approved
SafinamideSafinamide may increase the hypotensive activities of Amlodipine.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Amlodipine.Withdrawn
SalicylamideThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Salsalate.Approved
SaprisartanAmlodipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Amlodipine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Sarilumab.Approved, Investigational
SC-236The therapeutic efficacy of Amlodipine can be decreased when used in combination with SC-236.Experimental, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Amlodipine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Amlodipine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Amlodipine.Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Amlodipine.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Amlodipine.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amlodipine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Amlodipine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Amlodipine.Approved
SiltuximabThe serum concentration of Amlodipine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Amlodipine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Amlodipine.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Amlodipine.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Amlodipine.Approved, Investigational
SitaxentanAmlodipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Amlodipine.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Amlodipine.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Amlodipine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Amlodipine.Approved
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Amlodipine.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Amlodipine.Approved, Investigational
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Amlodipine.Approved
SotalolThe risk or severity of adverse effects can be increased when Amlodipine is combined with Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Amlodipine.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Amlodipine.Experimental
SpiraprilAmlodipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Amlodipine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Amlodipine.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Amlodipine.Experimental
StiripentolThe serum concentration of Amlodipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Amlodipine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amlodipine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Amlodipine.Approved
SulfasalazineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Sulindac.Approved, Investigational
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Amlodipine.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Amlodipine.Approved, Investigational
SuprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Suxibuzone.Experimental
TacrineThe serum concentration of Tacrine can be increased when it is combined with Amlodipine.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Amlodipine.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Amlodipine.Investigational
TalniflumateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Talniflumate.Approved
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Amlodipine.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Amlodipine.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Amlodipine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Amlodipine.Approved, Investigational
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Amlodipine.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Amlodipine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Amlodipine can be decreased when combined with Telithromycin.Approved
TelmisartanAmlodipine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilAmlodipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Amlodipine.Approved
TenidapThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Tenidap.Experimental
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Amlodipine.Approved
TenoxicamThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Amlodipine.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Amlodipine.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Amlodipine.Approved, Withdrawn
Testosterone propionateThe serum concentration of Testosterone propionate can be increased when it is combined with Amlodipine.Approved, Investigational, Vet Approved, Withdrawn
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Amlodipine.Approved, Vet Approved
TetrahydropalmatineAmlodipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Amlodipine.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the antihypertensive activities of Amlodipine.Approved
ThiamylalThiamylal may increase the hypotensive activities of Amlodipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Amlodipine.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Amlodipine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Amlodipine.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Amlodipine.Approved
TicrynafenAmlodipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe serum concentration of Timolol can be increased when it is combined with Amlodipine.Approved
TinoridineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Tinoridine.Investigational
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Amlodipine.Approved
TipranavirThe metabolism of Amlodipine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Amlodipine can be decreased when it is combined with Tocilizumab.Approved
TocopherylquinoneAmlodipine may increase the hypotensive activities of Tocopherylquinone.Experimental, Investigational
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Amlodipine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Amlodipine.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Tolmetin.Approved
TolonidineAmlodipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Amlodipine.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Amlodipine.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Amlodipine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Amlodipine.Approved, Investigational
TorasemideTorasemide may increase the hypotensive activities of Amlodipine.Approved
TrandolaprilAmlodipine may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Amlodipine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Amlodipine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Amlodipine.Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Amlodipine.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Amlodipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Amlodipine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Amlodipine is combined with Triamterene.Approved
TrichlormethiazideAmlodipine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Amlodipine.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Amlodipine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Amlodipine.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Amlodipine.Approved
Trolamine salicylateThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Trolamine salicylate.Approved
TroleandomycinThe metabolism of Amlodipine can be decreased when combined with Troleandomycin.Approved
TubocurarineAmlodipine may increase the neuromuscular blocking activities of Tubocurarine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Amlodipine.Approved, Investigational, Nutraceutical
UdenafilUdenafil may increase the antihypertensive activities of Amlodipine.Approved, Investigational
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Amlodipine.Approved
UnoprostoneAmlodipine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Amlodipine.Investigational
ValdecoxibThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
ValinomycinThe serum concentration of Valinomycin can be increased when it is combined with Amlodipine.Experimental
ValsartanValsartan may increase the hypotensive activities of Amlodipine.Approved, Investigational
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Amlodipine.Investigational
VardenafilVardenafil may increase the antihypertensive activities of Amlodipine.Approved
VecuroniumAmlodipine may increase the neuromuscular blocking activities of Vecuronium.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Amlodipine.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amlodipine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Amlodipine.Approved, Investigational
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Amlodipine.Approved
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Amlodipine.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Amlodipine.Approved
VincamineAmlodipine may increase the hypotensive activities of Vincamine.Experimental
VincristineThe excretion of Vincristine can be decreased when combined with Amlodipine.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Amlodipine.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Amlodipine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Amlodipine.Approved, Investigational
VoriconazoleThe metabolism of Amlodipine can be decreased when combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Amlodipine.Approved, Investigational
XipamideAmlodipine may increase the hypotensive activities of Xipamide.Experimental
YohimbineYohimbine may decrease the antihypertensive activities of Amlodipine.Approved, Investigational, Vet Approved
ZaltoprofenThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Amlodipine.Approved
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Amlodipine.Approved
ZofenoprilAmlodipine may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Zomepirac.Withdrawn
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Amlodipine.Approved, Investigational
Food Interactions
  • Avoid natural licorice.
  • Grapefruit down regulates post-translational expression of CYP3A4, the major metabolizing enzyme of amlodipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of amlodipine and may cause toxicity. Avoid grapefruit products while on this medication.
  • Take without regard to meals.

References

Synthesis Reference
US4572909
General References
  1. Nayler WG, Gu XH: The unique binding properties of amlodipine: a long-acting calcium antagonist. J Hum Hypertens. 1991 Aug;5 Suppl 1:55-9. [PubMed:1834847]
  2. van Zwieten PA: Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties. Clin Cardiol. 1994 Sep;17(9 Suppl 3):III3-6. [PubMed:9156957]
External Links
Human Metabolome Database
HMDB0005018
KEGG Drug
D07450
KEGG Compound
C06825
PubChem Compound
2162
PubChem Substance
46507214
ChemSpider
2077
ChEBI
2668
ChEMBL
CHEMBL1491
Therapeutic Targets Database
DAP000139
PharmGKB
PA448388
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Amlodipine
ATC Codes
C09DB05 — Irbesartan and amlodipineC09DB01 — Valsartan and amlodipineC09DB04 — Telmisartan and amlodipineC09DX03 — Olmesartan medoxomil, amlodipine and hydrochlorothiazideC09DX01 — Valsartan, amlodipine and hydrochlorothiazideC10BX11 — Atorvastatin, amlodipine and perindoprilC08GA02 — Amlodipine and diureticsC09DB06 — Losartan and amlodipineC09DB07 — Candesartan and amlodipineC09DB02 — Olmesartan medoxomil and amlodipineC10BX03 — Atorvastatin and amlodipineC09BB03 — Lisinopril and amlodipineC08CA01 — AmlodipineC09BB07 — Ramipril and amlodipineC10BX09 — Rosuvastatin and amlodipineC09BX01 — Perindopril, amlodipine and indapamideC10BX07 — Rosuvastatin, amlodipine and lisinoprilC09XA54 — Aliskiren, amlodipine and hydrochlorothiazideC09XA53 — Aliskiren and amlodipineC09BB04 — Perindopril and amlodipine
AHFS Codes
  • 24:28.08 — Dihydropyridines
FDA label
Download (91.4 KB)
MSDS
Download (74.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealhty1
1CompletedNot AvailableHealthy Volunteers14
1CompletedNot AvailableHealthy Volunteers / Pulmonary Disease, Chronic Obstructive1
1CompletedNot AvailableHigh Blood Pressure (Hypertension)3
1CompletedNot AvailableHypertension,Essential1
1CompletedBasic ScienceHigh Blood Pressure (Hypertension)1
1CompletedBasic ScienceHypertension(HTN)1
1CompletedDiagnosticHigh Blood Pressure (Hypertension)1
1CompletedOtherHigh Blood Pressure (Hypertension)1
1CompletedPreventionHealthy Volunteers / Pulmonary Disease, Chronic Obstructive1
1CompletedSupportive CareHealthy Male Volunteers1
1CompletedTreatmentBioequivalence1
1CompletedTreatmentCardiovascular Disease (CVD) / High Blood Pressure (Hypertension) / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentErectile Dysfunction (ED)1
1CompletedTreatmentFasting2
1CompletedTreatmentFed1
1CompletedTreatmentHealthy Male Volunteers1
1CompletedTreatmentHealthy Volunteers19
1CompletedTreatmentHigh Blood Pressure (Hypertension)9
1CompletedTreatmentHigh Blood Pressure (Hypertension) / Hyperlipidemias3
1CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
1CompletedTreatmentHypertension With Hyperlipidemia / Hypertention With Hyperlipidemia1
1CompletedTreatmentHypertension and Dyslipidemia1
1CompletedTreatmentType 2 Diabetes Mellitus1
1Not Yet RecruitingBasic ScienceHealthy Volunteers1
1Not Yet RecruitingTreatmentHealthy Volunteers1
1Not Yet RecruitingTreatmentHigh Blood Pressure (Hypertension)1
1RecruitingTreatmentHigh Blood Pressure (Hypertension) / Hyperlipidemias1
1TerminatedTreatmentHigh Blood Pressure (Hypertension) / Hyperlipidemias1
1Unknown StatusBasic ScienceHealthy Volunteers1
1WithdrawnTreatmentHepatitis C Viral Infection / High Blood Pressure (Hypertension)1
1, 2CompletedTreatmentPancreatitis1
1, 2RecruitingTreatmentMetastatic Triple Negative Breast Cancer1
2Active Not RecruitingPreventionHigh Blood Pressure (Hypertension) / Hyperlipidemias1
2CompletedNot AvailableConcurrent Obesity / High Blood Pressure (Hypertension)1
2CompletedTreatmentAbdominal Aortic Aneurysms (AAA)1
2CompletedTreatmentAngina, Prinzmetal's1
2CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / High Blood Pressure (Hypertension) / Vascular Diseases1
2CompletedTreatmentEndothelial Dysfunction / High Blood Pressure (Hypertension) / Insulin Resistance / Metabolic Syndromes1
2CompletedTreatmentHigh Blood Pressure (Hypertension)6
2CompletedTreatmentHypertension,Essential3
2RecruitingTreatmentHigh Blood Pressure (Hypertension)1
2RecruitingTreatmentHypertension,Essential1
2SuspendedTreatmentChronic Heart Failure (CHF)1
2TerminatedTreatmentAnkle Edema / High Blood Pressure (Hypertension)1
2TerminatedTreatmentHigh Blood Pressure (Hypertension) / Obesity, Abdominal1
2Unknown StatusTreatmentHypertension,Essential1
2, 3CompletedPreventionThalassaemic disorders1
2, 3CompletedTreatmentCardiac Failure / Congestive Heart Failure (CHF) / Heart Failure, Unspecified1
2, 3CompletedTreatmentGrade I or II Essential Hypertension1
2, 3CompletedTreatmentHypertension,Essential1
2, 3CompletedTreatmentThalassemia Major (TM)1
2, 3RecruitingPreventionCognitively Normal Older Adults / Family History of Alzheimer's Disease / High Blood Pressure (Hypertension) / Subjective Cognitive Decline1
2, 3RecruitingTreatmentHigh Blood Pressure (Hypertension) / Sleep Apnea Syndrome1
2, 3Unknown StatusTreatmentHypertension,Essential2
3CompletedDiagnosticHigh Blood Pressure (Hypertension)1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / Heart Failure, Unspecified / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Myocardial Infarction / Myocardial Ischemia1
3CompletedTreatmentChronic Kidney Disease (CKD) / High Blood Pressure (Hypertension)1
3CompletedTreatmentDyslipidemia With Hypertension1
3CompletedTreatmentDyslipidemias / High Blood Pressure (Hypertension)2
3CompletedTreatmentHigh Blood Pressure (Hypertension)59
3CompletedTreatmentHigh Blood Pressure (Hypertension) / Metabolic Syndromes1
3CompletedTreatmentHigh Blood Pressure (Hypertension) / Obstructive Sleep Apnea (OSA)1
3CompletedTreatmentHigh Blood Pressure (Hypertension) / Sleep Apnea Syndrome1
3CompletedTreatmentHigh Blood Pressure (Hypertension) / Transplantation, Kidney1
3CompletedTreatmentHypertension With Hyperlipidemia1
3CompletedTreatmentHypertension,Essential12
3CompletedTreatmentHypertension; Hypertrophy, Left Ventricular1
3CompletedTreatmentModerate to Severe Hypertension1
3CompletedTreatmentProteinuria1
3CompletedTreatmentAcute iron intoxication / Thalassaemic disorders1
3RecruitingTreatmentCerebral Small Vessels Disease1
3RecruitingTreatmentDyslipidemias / Hypertension,Essential1
3RecruitingTreatmentHigh Blood Pressure (Hypertension)1
3RecruitingTreatmentHigh Blood Pressure (Hypertension) / Hyperlipidemias2
3TerminatedTreatmentCardiovascular Events1
3Unknown StatusTreatmentDepression1
3Unknown StatusTreatmentDiabetes Mellitus (DM) / Hypertension,Essential1
3Unknown StatusTreatmentHypertension,Essential1
3WithdrawnTreatmentHigh Blood Pressure (Hypertension)2
4Active Not RecruitingBasic ScienceArterial hypoxia / Obstructive Sleep Apnea (OSA) / Sleep Apnea Syndrome1
4Active Not RecruitingTreatmentChronic Hypertension in Pregnancy1
4CompletedNot AvailableHigh Blood Pressure (Hypertension)1
4CompletedHealth Services ResearchAsthma Bronchial1
4CompletedOtherCoronary Artery Disease / Type 2 Diabetes Mellitus1
4CompletedPreventionCardiovascular Disease (CVD) / High Blood Pressure (Hypertension)1
4CompletedPreventionCoronary Artery Atherosclerosis / High Blood Pressure (Hypertension)1
4CompletedPreventionHigh Blood Pressure (Hypertension)2
4CompletedPreventionHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
4CompletedPreventionNonvalvular Atrial Fibrillation2
4CompletedPreventionWe Searched for the Effects of Calcium Channel Blocker Amlodipine on the Clinical and Laboratory Parameters of Diabetic Patients With Proteinuria1
4CompletedTreatmentAlbuminuria1
4CompletedTreatmentAlbuminuria / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
4CompletedTreatmentAngina Pectoris / High Blood Cholesterol Level / High Blood Pressure (Hypertension)1
4CompletedTreatmentAnginal Pain1
4CompletedTreatmentBMI >30 kg/m2 / Diabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4CompletedTreatmentBMI >30 kg/m2 / High Blood Pressure (Hypertension)1
4CompletedTreatmentBlood Pressures1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentChronic Renal Failure (CRF)1
4CompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4CompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension) / Proteinuria2
4CompletedTreatmentDiastolic Dysfunction / High Blood Pressure (Hypertension)1
4CompletedTreatmentDyslipidemias / High Blood Pressure (Hypertension)3
4CompletedTreatmentEssential Hypertension ( Mild to Moderate)1
4CompletedTreatmentHigh Blood Cholesterol Level / High Blood Pressure (Hypertension)1
4CompletedTreatmentHigh Blood Pressure (Hypertension)32
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Hyperlipidemias1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Hypertension,Essential1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Left Ventricle Hypertrophy1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Left Ventricular Hypertrophy1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Metabolic Syndromes1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Pharmacogenetics1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Strokes1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
4CompletedTreatmentHypertension,Essential5
4CompletedTreatmentIschaemic Heart Diseases1
4CompletedTreatmentMyocardial Ischemia1
4CompletedTreatmentStage 2 Systolic Hypertension1
4CompletedTreatmentStroke, Ischemic1
4Not Yet RecruitingTreatmentASCVD / High Blood Pressure (Hypertension) / Impaired Fasting Glucose (IFG)1
4Not Yet RecruitingTreatmentArterial Hypertension2
4Not Yet RecruitingTreatmentBlood Pressures / Cardiovascular Risk Factors / Prehypertension / Strokes / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentHigh Blood Pressure (Hypertension)1
4Not Yet RecruitingTreatmentQuality of Life1
4RecruitingDiagnosticAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD) / Overlap Syndrome1
4RecruitingDiagnosticHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
4RecruitingPreventionBlood Pressures / High Blood Pressure (Hypertension) / Strokes1
4RecruitingTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentArterial Hypertension1
4RecruitingTreatmentArterial Hypertension / Blood Pressures / Dyslipidemias / Lipid Metabolism Disorders1
4RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4RecruitingTreatmentEfficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension1
4RecruitingTreatmentHigh Blood Pressure (Hypertension)5
4RecruitingTreatmentNonalcoholic Fatty Liver Disease (NAFLD)1
4RecruitingTreatmentPediatric Hypertension1
4RecruitingTreatmentProteinuria / Renal Insufficiency,Chronic1
4RecruitingTreatmentPulmonary Disease, Chronic Obstructive1
4TerminatedNot AvailableHypertension and Cardiovascular Risk Factors1
4TerminatedPreventionAtherosclerosis / Carotid Artery Stenosis / Strokes1
4TerminatedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension) / Stage 2 Hypertension1
4TerminatedTreatmentHigh Blood Pressure (Hypertension)1
4TerminatedTreatmentHypertension With Metabolic Syndrome1
4Unknown StatusDiagnosticCoronary Artery Disease1
4Unknown StatusPreventionDiabetic Nephropathies1
4Unknown StatusTreatmentAlbuminuria / Diabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4Unknown StatusTreatmentArterial and Arteriolar Disorders1
4Unknown StatusTreatmentBlood Pressures1
4Unknown StatusTreatmentCoronary Artery Disease2
4Unknown StatusTreatmentDialysis therapy / High Blood Pressure (Hypertension)1
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension)5
4Unknown StatusTreatmentHypertension,Essential1
4WithdrawnDiagnosticBMI >30 kg/m2 / High Blood Pressure (Hypertension)1
4WithdrawnTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4WithdrawnTreatmentHigh Blood Pressure (Hypertension)2
Not AvailableActive Not RecruitingTreatmentBeta Thalassemia Major1
Not AvailableCompletedNot AvailableAngina Pectoris / Dyslipidemia (Fredrickson Type Ⅱa) / High Blood Cholesterol Level / High Blood Pressure (Hypertension)1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / High Blood Pressure (Hypertension) / Myocardial Infarction1
Not AvailableCompletedNot AvailableDiabetes Complications / Diabetes, Diabetes Mellitus Type 1 / Eye Diseases / Retinopathy, Diabetic1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)5
Not AvailableCompletedDiagnosticArterial Hypertension1
Not AvailableCompletedDiagnosticHigh Blood Pressure (Hypertension)1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / High Blood Pressure (Hypertension)1
Not AvailableCompletedTreatmentChronic Stable Angina Pectoris / High Blood Pressure (Hypertension) / Vasospastic Angina2
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
Not AvailableCompletedTreatmentFemale Infertility Associated With Anovulation1
Not AvailableCompletedTreatmentHeart Failure With Preserved Ejection Fraction (HFpEF) / Left Ventricular Hypertrophy/Hypertension / Pulmonary Diseases1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension)2
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Lower Urinary Tract Symptoms (LUTS)1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Plasma Renin Activity1
Not AvailableCompletedTreatmentHypertension,Essential1
Not AvailableCompletedTreatmentMyocardial Ischemia1
Not AvailableRecruitingNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableRecruitingNot AvailableHypertension,Essential1
Not AvailableRecruitingNot AvailableLower Leg Edema / Orthostatic Hypertension1
Not AvailableRecruitingNot AvailableMetabolic Syndromes1
Not AvailableRecruitingNot AvailableObesity, Morbid1
Not AvailableRecruitingDiagnosticHigh Blood Pressure (Hypertension)1
Not AvailableRecruitingTreatmentAcute iron intoxication / Beta-Thalassemia1
Not AvailableRecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableTerminatedTreatmentAbdominal Aortic Aneurysms (AAA) / High Blood Pressure (Hypertension)1
Not AvailableTerminatedTreatmentAortic Compliance / Diastolic Function / Insulin Sensitivity1
Not AvailableTerminatedTreatmentHigh Blood Pressure (Hypertension)1
Not AvailableUnknown StatusNot AvailableArterial Hypertension / Diabetes Mellitus (DM)1
Not AvailableUnknown StatusTreatmentBlood Pressure Variability / Intracranial Artery Stenosis1
Not AvailableUnknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableUnknown StatusTreatmentHigh Blood Pressure (Hypertension)1

Pharmacoeconomics

Manufacturers
  • Synthon pharmaceuticals inc
  • Actavis totowa llc
  • Alkem laboratories ltd
  • Amneal pharmaceuticals ny llc
  • Apotex inc
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Dr reddys laboratories ltd
  • Gedeon richter usa inc
  • Genpharm inc
  • Glenmark generics ltd
  • Invagen pharmaceuticals inc
  • Lek pharmaceuticals dd
  • Lupin ltd
  • Matrix laboratories ltd
  • Mutual pharmacal co
  • Mylan laboratories inc
  • Orchid healthcare
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Teva pharmaceuticals usa inc
  • Torrent pharmaceuticals ltd
  • Upsher smith laboratories inc
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • Wockhardt ltd
  • World gen llc
  • Zydus pharmaceuticals usa inc
  • Pfizer inc
  • Dr reddys laboratories inc
Packagers
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotex Inc.
  • AQ Pharmaceuticals Inc.
  • Arrow Pharm Malta Ltd.
  • A-S Medication Solutions LLC
  • Aurobindo Pharma Ltd.
  • Beijing Second Pharmaceutical Co. Ltd.
  • Blu Pharmaceuticals LLC
  • Breckenridge Pharmaceuticals
  • Bryant Ranch Prepack
  • Cadila Healthcare Ltd.
  • Camber Pharmaceuticals Inc.
  • Caraco Pharmaceutical Labs
  • Cardinal Health
  • Chemical Works Of Gedeon Richter Ltd.
  • Cobalt Pharmaceuticals Inc.
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • Dept Health Central Pharmacy
  • Direct Dispensing Inc.
  • Direct Pharmaceuticals Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • Glenmark Generics Ltd.
  • Greenstone LLC
  • H.E. Butt Grocery Co.
  • Heartland Repack Services LLC
  • InvaGen Pharmaceuticals Inc.
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Letco Medical Inc.
  • Lupin Pharmaceuticals Inc.
  • Major Pharmaceuticals
  • Medisca Inc.
  • Medvantx Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neuman Distributors Inc.
  • Norwich Pharmaceuticals Inc.
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Promius Pharma
  • Qualitest
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Roxane Labs
  • Sandhills Packaging Inc.
  • Secan Pharmaceuticals Inc.
  • Solco Healthcare US LLC
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Stat Scripts LLC
  • Synthon Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals
  • Tya Pharmaceuticals
  • UDL Laboratories
  • US Pharmaceutical Group
  • USL Pharma Inc.
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Warner Lambert Company LLC
  • Wockhardt Ltd.
  • Zydus Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral
TabletOral10 mg/1
TabletOral2.5 mg/1
TabletOral5 mg/1
CapsuleOral
TabletOral10.00 mg
TabletOral5.00 mg
Kit
TabletOral10.0 mg
TabletOral5.0 mg
TabletOral10 mg
TabletOral5 mg
TabletOral2.5 mg
Tablet, film coatedOral
Tablet, multilayerOral
Prices
Unit descriptionCostUnit
Amlodipine besylate powder9.99USD g
Lotrel 10-40 mg capsule5.21USD capsule
Lotrel 10-20 mg capsule4.8USD capsule
Lotrel 5-40 mg capsule4.37USD capsule
Lotrel 5-20 mg capsule4.13USD capsule
Lotrel 5-10 mg capsule3.91USD capsule
Lotrel 2.5-10 mg capsule3.83USD capsule
Norvasc 10 mg tablet3.16USD tablet
Amlodipine besylate 10 mg tablet2.42USD tablet
Norvasc 2.5 mg tablet2.36USD tablet
Norvasc 5 mg tablet2.36USD tablet
Norvasc 10 mg Tablet2.14USD tablet
Amlodipine besylate 2.5 mg tablet1.76USD tablet
Amlodipine besylate 5 mg tablet1.76USD tablet
Norvasc 5 mg Tablet1.44USD tablet
Amlodipine 10 mg Tablet1.03USD tablet
Apo-Amlodipine 10 mg Tablet1.03USD tablet
Co Amlodipine 10 mg Tablet1.03USD tablet
Gd-Amlodipine 10 mg Tablet1.03USD tablet
Jamp-Amlodipine 10 mg Tablet1.03USD tablet
Mylan-Amlodipine 10 mg Tablet1.03USD tablet
Novo-Amlodipine 10 mg Tablet1.03USD tablet
Phl-Amlodipine 10 mg Tablet1.03USD tablet
Pms-Amlodipine 10 mg Tablet1.03USD tablet
Ran-Amlodipine 10 mg Tablet1.03USD tablet
Ratio-Amlodipine 10 mg Tablet1.03USD tablet
Sandoz Amlodipine 10 mg Tablet1.03USD tablet
Amlodipine 5 mg Tablet0.7USD tablet
Apo-Amlodipine 5 mg Tablet0.7USD tablet
Co Amlodipine 5 mg Tablet0.7USD tablet
Gd-Amlodipine 5 mg Tablet0.7USD tablet
Jamp-Amlodipine 5 mg Tablet0.7USD tablet
Mylan-Amlodipine 5 mg Tablet0.7USD tablet
Novo-Amlodipine 5 mg Tablet0.7USD tablet
Phl-Amlodipine 5 mg Tablet0.7USD tablet
Pms-Amlodipine 5 mg Tablet0.7USD tablet
Ran-Amlodipine 5 mg Tablet0.7USD tablet
Ratio-Amlodipine 5 mg Tablet0.7USD tablet
Sandoz Amlodipine 5 mg Tablet0.7USD tablet
Phl-Amlodipine 2.5 mg Tablet0.35USD tablet
Pms-Amlodipine 2.5 mg Tablet0.35USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2170278No1999-08-032014-08-10Canada
US6162802No1997-12-192017-12-19Us
US5969156Yes1997-01-082017-01-08Us
US6294197Yes1997-12-182017-12-18Us
US5559111Yes1999-01-212019-01-21Us
US6395728No1999-07-082019-07-08Us
US6828339No2002-11-202022-11-20Us
US5616599Yes1996-10-252016-10-25Us
US6455574No1998-08-112018-08-11Us
US8101599No2003-05-162023-05-16Us
US8475839Yes2003-11-162023-11-16Us
US8613949No2009-12-212029-12-21Us
US8618174No2001-11-152021-11-15Us
US8183295No2003-05-162023-05-16Us
US7846961No2009-10-052029-10-05Us
US6696481No2003-04-152023-04-15Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)178-179 °CNot Available
water solubility75.3 mg/LNot Available
logP3.00AUSTIN,RP ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0074 mg/mLALOGPS
logP2.22ALOGPS
logP1.64ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)19.12ChemAxon
pKa (Strongest Basic)9.45ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.88 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity108.64 m3·mol-1ChemAxon
Polarizability42.31 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9479
Blood Brain Barrier-0.7744
Caco-2 permeable-0.5468
P-glycoprotein substrateSubstrate0.9102
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.8473
Renal organic cation transporterNon-inhibitor0.803
CYP450 2C9 substrateNon-substrate0.8627
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6967
CYP450 1A2 substrateInhibitor0.538
CYP450 2C9 inhibitorInhibitor0.514
CYP450 2D6 inhibitorNon-inhibitor0.7626
CYP450 2C19 inhibitorInhibitor0.5871
CYP450 3A4 inhibitorInhibitor0.8608
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6642
Ames testNon AMES toxic0.7605
CarcinogenicityNon-carcinogens0.8568
BiodegradationNot ready biodegradable0.9791
Rat acute toxicity2.5396 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8302
hERG inhibition (predictor II)Inhibitor0.8411
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4u-0192000000-988fbef9dd83defbfbe0
MS/MS Spectrum - , positiveLC-MS/MSsplash10-002o-1392000000-3e9bc5dcf61b0f4cae6a
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Chlorobenzenes / Aryl chlorides / Dicarboxylic acids and derivatives / Vinylogous amides / Methyl esters / Enoate esters / Amino acids and derivatives / Azacyclic compounds / Dialkyl ethers / Dialkylamines
show 7 more
Substituents
Dihydropyridinecarboxylic acid derivative / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Vinylogous amide / Alpha,beta-unsaturated carboxylic ester
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
ethyl ester, primary amino compound, methyl ester, monochlorobenzenes, dihydropyridine (CHEBI:2668)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB2
Uniprot ID
Q08289
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1B
Uniprot ID
Q00975
Uniprot Name
Voltage-dependent N-type calcium channel subunit alpha-1B
Molecular Weight
262493.84 Da
References
  1. Furukawa T, Nukada T, Suzuki K, Fujita Y, Mori Y, Nishimura M, Yamanaka M: Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br J Pharmacol. 1997 Jul;121(6):1136-40. [PubMed:9249249]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060]
  3. Miyashita Y, Furukawa T, Kamegaya E, Yoshii M, Nukada T: A region of N-type Ca(2+) channel critical for blockade by the dihydropyridine amlodipine. Eur J Pharmacol. 2010 Apr 25;632(1-3):14-22. doi: 10.1016/j.ejphar.2010.01.006. Epub 2010 Jan 22. [PubMed:20097194]
  4. Murakami M, Nakagawasai O, Fujii S, Kameyama K, Murakami S, Hozumi S, Esashi A, Taniguchi R, Yanagisawa T, Tan-no K, Tadano T, Kitamura K, Kisara K: Antinociceptive action of amlodipine blocking N-type Ca2+ channels at the primary afferent neurons in mice. Eur J Pharmacol. 2001 May 11;419(2-3):175-81. [PubMed:11426839]
  5. Ogihara T, Kano T, Kakinuma C: Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling. Arzneimittelforschung. 2009;59(6):283-8. doi: 10.1055/s-0031-1296398. [PubMed:19634509]
  6. Qu YL, Sugiyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T: Comparison of binding affinities of omega-conotoxin and amlodipine to N-type Ca2+ channels in rat brain. Zhongguo Yao Li Xue Bao. 1998 Mar;19(2):97-100. [PubMed:10374627]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated ion channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name
CACNA2D3
Uniprot ID
Q8IZS8
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-3
Molecular Weight
123010.22 Da
References
  1. Furukawa T, Nukada T, Suzuki K, Fujita Y, Mori Y, Nishimura M, Yamanaka M: Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br J Pharmacol. 1997 Jul;121(6):1136-40. [PubMed:9249249]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060]
  3. Miyashita Y, Furukawa T, Kamegaya E, Yoshii M, Nukada T: A region of N-type Ca(2+) channel critical for blockade by the dihydropyridine amlodipine. Eur J Pharmacol. 2010 Apr 25;632(1-3):14-22. doi: 10.1016/j.ejphar.2010.01.006. Epub 2010 Jan 22. [PubMed:20097194]
  4. Murakami M, Nakagawasai O, Fujii S, Kameyama K, Murakami S, Hozumi S, Esashi A, Taniguchi R, Yanagisawa T, Tan-no K, Tadano T, Kitamura K, Kisara K: Antinociceptive action of amlodipine blocking N-type Ca2+ channels at the primary afferent neurons in mice. Eur J Pharmacol. 2001 May 11;419(2-3):175-81. [PubMed:11426839]
  5. Ogihara T, Kano T, Kakinuma C: Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling. Arzneimittelforschung. 2009;59(6):283-8. doi: 10.1055/s-0031-1296398. [PubMed:19634509]
  6. Qu YL, Sugiyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T: Comparison of binding affinities of omega-conotoxin and amlodipine to N-type Ca2+ channels in rat brain. Zhongguo Yao Li Xue Bao. 1998 Mar;19(2):97-100. [PubMed:10374627]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
High voltage-gated calcium channel activity
Specific Function
Not Available
Gene Name
CACNB1
Uniprot ID
Q6TME4
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-1
Molecular Weight
23836.425 Da
References
  1. Furukawa T, Nukada T, Suzuki K, Fujita Y, Mori Y, Nishimura M, Yamanaka M: Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br J Pharmacol. 1997 Jul;121(6):1136-40. [PubMed:9249249]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060]
  3. Miyashita Y, Furukawa T, Kamegaya E, Yoshii M, Nukada T: A region of N-type Ca(2+) channel critical for blockade by the dihydropyridine amlodipine. Eur J Pharmacol. 2010 Apr 25;632(1-3):14-22. doi: 10.1016/j.ejphar.2010.01.006. Epub 2010 Jan 22. [PubMed:20097194]
  4. Murakami M, Nakagawasai O, Fujii S, Kameyama K, Murakami S, Hozumi S, Esashi A, Taniguchi R, Yanagisawa T, Tan-no K, Tadano T, Kitamura K, Kisara K: Antinociceptive action of amlodipine blocking N-type Ca2+ channels at the primary afferent neurons in mice. Eur J Pharmacol. 2001 May 11;419(2-3):175-81. [PubMed:11426839]
  5. Ogihara T, Kano T, Kakinuma C: Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling. Arzneimittelforschung. 2009;59(6):283-8. doi: 10.1055/s-0031-1296398. [PubMed:19634509]
  6. Qu YL, Sugiyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T: Comparison of binding affinities of omega-conotoxin and amlodipine to N-type Ca2+ channels in rat brain. Zhongguo Yao Li Xue Bao. 1998 Mar;19(2):97-100. [PubMed:10374627]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. Puscas I, Gilau L, Coltau M, Pasca R, Domuta G, Baican M, Hecht A: Hypotensive effect of calcium channel blockers is parallel with carbonic anhydrase I inhibition. Clin Pharmacol Ther. 2000 Oct;68(4):443-9. [PubMed:11061585]
  2. Puscas L, Gilau L, Coltau M, Pasca R, Domuta G, Baican M, Hecht A: Calcium channel blockers reduce blood pressure in part by inhibiting vascular smooth muscle carbonic anhydrase I. Cardiovasc Drugs Ther. 2000 Oct;14(5):523-8. [PubMed:11101200]
  3. Puscas I, Coltau M, Baican M, Pasca R, Domuta G, Hecht A: Vasoconstrictive drugs increase carbonic anhydrase I in vascular smooth muscle while vasodilating drugs reduce the activity of this isozyme by a direct mechanism of action. Drugs Exp Clin Res. 2001;27(2):53-60. [PubMed:11392054]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sphingomyelin phosphodiesterase activity
Specific Function
Converts sphingomyelin to ceramide. Also has phospholipase C activities toward 1,2-diacylglycerolphosphocholine and 1,2-diacylglycerolphosphoglycerol. Isoform 2 and isoform 3 have lost catalytic ac...
Gene Name
SMPD1
Uniprot ID
P17405
Uniprot Name
Sphingomyelin phosphodiesterase
Molecular Weight
69751.3 Da
References
  1. Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, Muhle C, Terfloth L, Groemer TW, Spitzer GM, Liedl KR, Gulbins E, Tripal P: Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One. 2011;6(8):e23852. doi: 10.1371/journal.pone.0023852. Epub 2011 Aug 31. [PubMed:21909365]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52. [PubMed:10805063]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52. [PubMed:10805063]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52. [PubMed:10805063]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52. [PubMed:10805063]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res. 2000 Oct;17(10):1189-97. [PubMed:11145223]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:39